Dando Toni M, Keating Gillian M
Adis International Limited, Auckland, New Zealand.
Drugs. 2005;65(17):2533-51. doi: 10.2165/00003495-200565170-00008.
Quetiapine (Seroquel), an atypical antipsychotic with established efficacy in the treatment of schizophrenia, shows efficacy in the treatment of acute mania and depression associated with bipolar disorder.Quetiapine, either as monotherapy or in combination with lithium or divalproex sodium (valproate semisodium), is generally well tolerated and effective in reducing manic symptoms in adult and adolescent patients with acute bipolar mania, and is approved for use in adults for this indication. As monotherapy, the drug is also effective in reducing depressive symptoms in patients with bipolar depression. It is associated with a low incidence of extrapyramidal symptom (EPS)-related adverse events and low EPS ratings in bipolar disorder. Quetiapine thus shows potential in the treatment of bipolar depression, and represents a useful agent for the treatment of acute bipolar mania.
喹硫平（思瑞康）是一种非典型抗精神病药物，已证实对精神分裂症的治疗有效，对双相情感障碍相关的急性躁狂和抑郁也有疗效。喹硫平无论是单药治疗还是与锂盐或丙戊酸钠（丙戊酸半钠）联合使用，在成年和青少年急性双相躁狂患者中通常耐受性良好且能有效减轻躁狂症状，已获批用于成年患者的这一适应症。作为单药治疗，该药物对双相抑郁患者减轻抑郁症状也有效。它与双相情感障碍中锥体外系症状（EPS）相关不良事件的发生率低以及EPS评分低有关。因此，喹硫平在双相抑郁的治疗中显示出潜力，是治疗急性双相躁狂的一种有用药物。
